What's new? Log in Free sign up

Table search / Ownership / Pacific Biosciences of California, Inc.

130 results

Newest first

PACB Pacific Biosciences of California, Inc.

Quarterly report

Three Months Ended September 30,	Nine Months Ended September 30,
(in thousands, except per share amounts)			2024			2023			2024			2023
Revenue:			Product revenue			$	35,296	$	51,562	$	102,051	$	129,871	Service and other revenue	4,671		4,129	12,739	12,293	Total revenue	39,967		55,691	114,790	142,164	Cost of Revenue:	Cost of product revenue			23,278		33,551	68,808	87,147	Cost of service and other revenue	3,484		4,054	10,588	11,258	Amortization of acquired intangible assets	3,201		184	7,172	550	Loss on purchase commitment	—		—	998	—	Total cost of revenue	29,963		37,789	87,566	98,955	Gross profit	10,004		17,902	27,224	43,209	Operating Expense:	Research and development			25,516		47,514	107,456	142,626	Sales, general and administrative	43,746		43,431	133,376	123,822	Goodwill impairment	—		—	93,200	—	Merger-related expenses	—		8,979	—	8,979	Amortization of acquired intangible assets	3,649		741	13,377	741	Change in fair value of contingent consideration	1,170		(271)	1,100	13,960	Total operating expense	74,081		100,394	348,509	290,128	Operating loss	(64,077)		(82,492)	(321,285)	(246,919)	Loss on extinguishment of debt	—		—	—	(2,033)	Interest expense	(3,538)		(3,588)	(10,655)	(10,772)	Other income, net	6,890		8,505	19,718	24,301	Loss before benefit from income taxes	(60,725)		(77,575)	(312,222)	(235,423)	Benefit from income taxes	—		(10,706)	—	(10,706)	Net loss	(60,725)		(66,869)	(312,222)	(224,717)	Other comprehensive income:	Unrealized gain on investments			2,076		846	1,334	2,925	Comprehensive loss	$	(58,649)	$	(66,023)	$	(310,888)	$	(221,792)	Net loss per share:	Basic			$	(0.22)	$	(0.26)	$	(1.15)	$	(0.90)	Diluted	$	(0.22)	$	(0.26)	$	(1.15)	$	(0.90)	Weighted average shares outstanding used in calculating net loss per share:	Basic			272,915			255,001			271,631			249,082
Diluted			272,915			255,001			271,631			249,082

8 Nov 24

7:28pm

PACB Pacific Biosciences of California, Inc.

Quarterly report

Nine Months Ended September 30, 2024
Common Stock			Additional Paid-in Capital			Accumulated Other Comprehensive Income			Accumulated Deficit			Total Stockholders' Equity
(in thousands)			Shares			Amount			Balance at December 31, 2023			267,744			$			268	$	2,539,892	$	219	$	(1,839,075)	$	701,304	Net loss	—			—			—	—	(312,222)	(312,222)	Other comprehensive income	—			—			—	1,334	—	1,334	Issuance of common stock in conjunction with equity plans	6,068			6			7,697	—	—	7,703	Share-based compensation expense	—			—			55,003	—	—	55,003	Balance at September 30, 2024	273,812			$			274	$	2,602,592	$	1,553	$	(2,151,297)	$	453,122

8 Nov 24

7:28pm

PACB Pacific Biosciences of California, Inc.

Quarterly report

The net carrying amount of the liability for the 2030 Notes is included as convertible senior notes, net, non-current in the Condensed Consolidated Balance Sheets as follows:

(in thousands)	September 30, 2024			December 31, 2023
Principal amount			$	441,000	$	441,000	Unamortized debt premium	471		524	Unamortized debt issuance costs	(6,197)		(6,907)	Net carrying amount	$	435,274	$	434,617

8 Nov 24

7:28pm

PACB Pacific Biosciences of California, Inc.

Quarterly report

The following table summarizes stock option activity for time-based awards:

(shares in thousands)	Number of shares			Weighted average exercise price
Outstanding at December 31, 2023			13,011			$			10.63	Granted	493			1.99			Exercised	(515)			3.15			Canceled	(1,474)			9.35			Expired	(287)			5.70			Outstanding at September 30, 2024	11,228			$			10.88

8 Nov 24

7:28pm

PACB Pacific Biosciences of California, Inc.

Quarterly report

Three Months Ended September 30, 2024
Common Stock			Additional Paid-in Capital			Accumulated Other Comprehensive (Loss) Income			Accumulated Deficit			Total Stockholders' Equity
(in thousands)			Shares			Amount			Balance at June 30, 2024			272,491			$			272	$	2,583,523	$	(523)	$	(2,090,572)	$	492,700	Net loss	—			—			—	—	(60,725)	(60,725)	Other comprehensive income	—			—			—	2,076	—	2,076	Issuance of common stock in conjunction with equity plans	1,321			2			810	—	—	812	Share-based compensation expense	—			—			18,259	—	—	18,259	Balance at September 30, 2024	273,812			$			274	$	2,602,592	$	1,553	$	(2,151,297)	$	453,122

8 Nov 24

7:28pm

Quarterly report

8 Nov 24

7:28pm

Quarterly report

8 Nov 24

7:28pm

Quarterly report

8 Nov 24

7:28pm

Quarterly report

8 Nov 24

7:28pm

qu4ug6ldvh i1vsy23a0

Quarterly report

8 Nov 24

7:28pm

nsxug vlp4wcjbtmks

Quarterly report

8 Nov 24

7:28pm

3ji9w5ipjxi sp9ei

Quarterly report

8 Nov 24

7:28pm

oaaka ektiv5751f

Quarterly report

8 Nov 24

7:28pm

Quarterly report

8 Nov 24

7:28pm

Quarterly report

8 Nov 24

7:28pm

Quarterly report

8 Nov 24

7:28pm

Quarterly report

8 Nov 24

7:28pm

Quarterly report

8 Nov 24

7:28pm

Quarterly report

8 Nov 24

7:28pm

w8pxnhs51uvf0w3

Quarterly report

8 Nov 24

7:28pm

Prev
1
2
3
4
5
...
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.